Developing orally inhaled and nasal drug products (OINDPs) is a high-stakes challenge with one of the lowest regulatory approval rates in the pharmaceutical industry. Late-stage failures often stem from overlooking human usage early in development, leading to costly delays, reformulations, or outright rejections. The complexity of OINDPs lies in the interplay of formulation, delivery device, and patient interaction—factors that, if misaligned, can derail even the most promising products. Don’t let your project become another statistic in the OINDP approval graveyard.
Join us to discover how human-realistic deposition testing can transform your OINDP development process. Using advanced tools like nasal casts with breathing simulators and measuring the ergonomics of actuating a nasal spray or inhaler, and deposition of orally inhaled drugs. We will demonstrate how to replicate real-world patient interactions early in development. You’ll learn practical strategies to measure critical parameters—such as nasal and orally inhaled deposition and patient actuation velocities, accelerations and hold times —and integrate them into your testing protocols, reducing risks and streamlining your path to regulatory approval.
Don’t miss this opportunity to gain a competitive edge in OINDP development. Register now for our webinar and learn how to leverage human-realistic deposition testing to de-risk your projects and achieve regulatory success. Secure your spot today and take the first step toward transforming your approach to OINDP development!
Key Learning Objectives:
- Understand the unique complexities of developing and testing orally inhaled and nasal drug products (OINDPs).
- Discover how human-realistic testing accelerates OINDP development by addressing patient interaction early.
- Recognize how nasal or inhaler deposition data can help advance the drug development process.
- Learn how to integrate human-realistic parameters into OINDP development and testing workflows.
